Article Text

PDF
Significant Association Between Polymorphisms of Wnt Antagonist Genes and Lung Cancer
  1. Meral Yilmaz, PhD*,
  2. Gonca Donmez, PhD,
  3. Turgut Kacan, MD,
  4. Ismail Sari, PhD§,
  5. Nalan Akgül Babacan, MD,
  6. Musa Sari, PhD,
  7. Saadettin Kilickap, MD**
  1. From the *Departments of Research Centre, †Medical Biology, ‡Medical Oncology, and §Biochemistry, Cumhuriyet University, Faculty of Medicine, Sivas; ∥Department of Medical Oncology, Marmara University, Faculty of Medicine, Istanbul; ¶Department of Biology, Cumhuriyet University, Faculty of Science, Sivas; and **Department of Medical Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey.
  1. Reprints: Meral Yilmaz, PhD, Department of Research Centre, Cumhuriyet University, Faculty of Medicine, 58140 Sivas, Turkey. E-mail: meralylmz{at}cumhuriyet.edu.tr.
  2. Supported by Cumhuriyet University Research Committee Grant T-504.

Abstract

Further elucidation of the molecular mechanisms underlying lung cancer (LC) is essential for the development of new effective therapeutic agents. Recently, involvement of Wnt antagonists in oncogenesis has been demonstrated in several cancers. The investigation of their contribution to lung carcinogenesis is still under investigation. We aimed to investigate whether there is a susceptibility or preventive effect of Wnt antagonist gene polymorphisms on the development and/or prognosis of LC. We investigated 110 LC patients and 160 controls. Single-nucleotide polymorphisms of Wnt antagonist genes including DKK2 (rs17037102), DKK3 (rs3206824), DKK3 intron4 G/C (rs7396187), DKK4 (rs2073664), and sFRP4 (rs1802074) were analyzed using nested polymerase chain reaction and restriction fragment length polymorphism. Results showed that patients with DKK3 AA compared with controls have a decreased risk of LC (adjusted for smoking habit, body mass index, and familial history) (P = 0.02; odds ratio [OR],0.08; 95% confidence interval [95% CI], 0.01–0.7). It was found that, for sFRP4 polymorphism, patients with GG and GA genotypes versus AA genotype controls showed a decreased risk for LC (P = 0.01; [OR, 0.19; 95% CI, 0.05–0.73 for GG genotype]; [OR = 0.18, 95% CI, 0.04–0.72 for GA genotype]). In addition, a decreased risk of LC was also found for the genotype combination of DKK3 (rs3206824) GG and sFRP4 AG + GG (P = 0.004; OR, 0.12; 95% CI, 0.02–0.58). We suggest that these 2 polymorphisms have a protective effect on LC in this study.

Key Words
  • DKK genes
  • lung cancer
  • polymorphism
  • sFRP4 gene

Statistics from Altmetric.com

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.